

Hodjattallah Rabbani, Ph.D

Associate Professor of Experimental Oncology

Personal Information

Date of Birth: Feb 12th, 1960

Place of Birth: Tehran, Iran

Nationality: Iranian

Institution: Monoclonal Antibody Research Center, Avicenna Research Institute

Work Address: Shahid Beheshti University, Chamran Expressway, Tehran, Iran
National Institute of Genetic Engineering and Biotechnology (NIGEB)

Tel: +98 21 22432020, Ext. 404

e-mail: rabbani@avicenna.ac.ir

e-mail: hodrab@gmail.com

e-mail: h_rabbani@nigeb.ac.ir

Number of publications: 129

H-index: 37 Google Scholar

February 8, 2025

Educational Background

- *Ph.D., Molecular Immunology*, Karolinska Institute, Department of Biosciences at NOVUM Sweden; 1990-1997
- *M.Sc., Medical Microbiology*, Medical Science University of Tehran, Tehran, Iran; 1985-1988
- *B.Sc., Laboratory Sciences*, Shahid Beheshti University, Tehran, Iran; 1980-1984

Executive Experience

Founder of PADZA PADTAN PAJHOOH Company (www.padzaco.com) (2017) which is active in the field of developing monoclonal antibodies for **detecting infectious diseases** and also **developing cancer diagnostic and therapeutic tools**. Currently, I am working as Chief Scientific Officer (CSO) at PADZA.

Academic Experience

Dec. 2024-current: Deputy of Research of the National Institute of Genetic Engineering and Biotechnology

Dec. 2023-Dec. 2024: Head of the Institute of Medical Biotechnology at National Institute of Genetic Engineering and Biotechnology

2017-current: Head of Antigen and Antibody Engineering Group, Avicenna Research Institute, Tehran, Iran

2016-2017: Head of Monoclonal Antibody Research Center, Avicenna Research Institute, Tehran, Iran

2005-2016: Head of Antigen and Antibody Engineering Group, Avicenna Research Institute, Tehran, Iran

1999-2011: Head of laboratory at Prof. Håkan Mellstedt's group, Associate Professor in Experimental Oncology, Department of Oncology-Pathology, University Hospital of Karolinska, Stockholm, Sweden

1997-1999: Postdoctoral Fellow in Karolinska Hospital, Cancer Center Karolinska, Stockholm, Sweden

Publications

1. Sanavandi M, Aalikhani K, Shafiee M, **Rabbani H**, Fazli G, Sadeghi N, Shokri B. A One-Step Plasma Assisted Synthesis of Gold Nanoparticles and Simultaneous Linker-Free Conjugation with Nestin: An In Vitro Study of Cellular Toxicity. **Nano Lett.** 2025 Feb 5;25(5):1974-1983. doi: 10.1021/acs.nanolett.4c05641. **Epub 2025** Jan 27. PMID: 39868719.
2. Chapter 2: Lab-on-a-chip: A Road Map of Silicon Chemistry to Multipurpose Microfluidic Chips. Neshat Askarzadeh ; Javad Mohammadi ; **Hodjattallah Rabbani** ; Morteza Hosseini. Detection Science Series. **2024 eBook Collection. Detection Science Series**, Page: 33 – 72, Doi:<https://doi.org/10.1039/9781837673476-00033>
3. Mehrdad Fathi Kazerouni, Hadi Shirzad, Ali Firoozbakhtian, Morteza Hosseini, **Hodjattallah Rabbani**, Seyed Amin Mousavinezhad, Mohammad Panji, A Ti3C2 modified single electrode electrochemical system for the gold nanoprism-enhanced ECL detection of HER2, **Journal of Electroanalytical Chemistry**, Volume 956, **2024**
4. Adel S, Firoozbakhtian A, **Rabbani H**, Hosseini M, Pebdeni AB, Sadeghi N, Gilnezhad J, Ganjali MR. COVID-19 electrochemical immunosensor with Ag-MOF: Rapid and high-selectivity nasal swab testing for effective detection. **Anal Biochem.** 2024 Jun;689:115500. doi: 10.1016/j.ab.2024.115500. Epub **2024** Feb 29. PMID: 38431139.
5. Amoabediny G, Khakbiz M, Jafarkhani S, Mohammadi J, Ilanlou S, Khajouei F, Lotfi L, **Rabbani H**, Ravasjani SA, Rahimi F, Lee KB. The effect of Nano-liposomal sodium nitrite on smooth muscle cell growth in a tissue-engineered small-diameter vascular graft. **Artif Organs.** 2023 Jul;47(7):1104-1121. doi: 10.1111/aor.14512. Epub **2023** Apr 4. PMID: 36820496.
6. Jahangirian E, Zargan J, **Rabbani H**, Zamani J. Investigating the inhibitory and penetrating properties of three novel anticancer and antimicrobial scorpion peptides via molecular docking and molecular dynamic simulation. **J Biomol Struct Dyn.** 2023;41(24):15354-15385. doi: 10.1080/07391102.2023.2188956. Epub **2023** Mar 16. PMID: 36927377.
7. Cell Surface Vimentin Detection in Cancer Cells by Peptide-Based Monoclonal Antibody. Niloufar Sadeghi, Ghazaleh Fazli, Ali Ahmad Bayat, Raminasadat Fatemi, Nasim Ebrahimnejhad, Ali Salimi, Omid Zarei , and **Hodjattallah Rabbani***. **AJMB**, Volume 15, Issue 2, 68-75.**2023**
8. Derhambakhsh S, Mohammadi J, Shokrgozar MA, **Rabbani H**, Sadeghi N, Nekounam H, Mohammadi S, Lee KB, Khakbiz M. Investigation of electrical stimulation on phenotypic vascular smooth muscle cells differentiation in tissue-engineered small-diameter vascular graft. **Tissue Cell.** **2023** Apr;81:101996. doi: 10.1016/j.tice.2022.101996. Epub **2022** Dec 13. PMID: 36657256.

9. Diagnostic and Therapeutic Implications of Sortilin Expressed on the Surface of Bladder Carcinoma Cells. Ali-Ahmad Bayat, Niloufar Sadeghi, Ghazaleh Fazli, Mohammad Reza Nowroozi, Solmaz Ohadian Moghadam, Amin Radmanesh, Mohammadjavad Hedayatshodeh, Ali Reza Sarrafzadeh, Omid Zarei, Fatemeh Ghaemimanesh, **Hodjattallah Rabbani***. Iran J Pathol. **2022**; 17(2): 174-182

10. A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer. Mozhan Haji Ghaffari · Miganoosh Simonian · Ali Salimi · Ebrahim Mirzadegan · Niloufar Sadeghi · Mohammad-Reza Nejadmoghaddam · Nasim Ebrahimnezhad · Ghazaleh Fazli · Ramina Fatemi · Ali-Ahmad Bayat · Mohammadali Mazloomi · **Hodjattallah Rabbani**. Breast Cancer. <https://doi.org/10.1007/s12282-022-01393-7>. **2022**

11. Jafarkhani S, Khakbiz M, Amoabediny G, Mohammadi J, Tahmasebipour M, **Rabbani H**, Salimi A, Lee KB. A novel co-culture assay to evaluate the effects of sympathetic innervation on vascular smooth muscle differentiation. **Bioorg Chem**. 2023 Apr;133:106233. doi: 10.1016/j.bioorg.2022.106233. Epub **2022** Nov 21. PMID: 36731293.

12. **The Association of Cell Surface Fibromodulin Expression and Bladder Carcinoma**. Ali Ahmad Bayat, Niloufar Sadeghi, Ali Salimi, Ghazaleh Fazli, Mohammad Reza Nowroozi, Solmaz Ohadian Moghadam, Amin Radmanesh, Mohsen Tabasi, Ali Reza Sarrafzadeh, Omid Zarei, **Hodjattallah Rabbani***. UROLOGICAL ONCOLOGY. Vol 19 No. 3/**2022**

13. Development of sandwich electrochemiluminescence immunosensor for COVID-19 diagnosis by SARS-CoV-2 spike protein detection based on Au@BSA-luminol nanocomposites. Morteza Hosseini*, Ebtessam Sobhanie, Foad Salehnia, Guobao Xu, **Hodjattallah Rabbani**, Mahsa Naghavi Sheikholeslami, Ali Firoozbakhtian, Niloufar Sadeghi, Mohammad Hossein Farajollah, Mohammad Reza Ganjali, Houman Vosough. **Bioelectrochemistry** **147** (2022)

14. An Anti-TAZ Monoclonal Antibody Recognizing Cell Surface Expressed TAZ Protein in Human Tumor Cells. Mozhan Haji Ghaffari, Mahsa Mohammadzadeh, Miganoosh Simonian, Mehrdad Hashemi, Niloufar Sadeghi, Babak Negahdari, Mohammadali Mazloomi, and **Hodjattallah Rabbani**. Avicenna Journal of Medical Biotechnology. Volume 15, Issue no. 1, 2022

15. Developing of specific monoclonal recombinant antibody fused to alkaline phosphatase (AP) for one-step detection of fig mosaic virus. Niloufar Rajabi · Mohammad Reza Safarnejad · Farshad Rakhshandehroo · Masoud Shamsbakhsh · **Hodjattallah Rabbani**. Biotech (2022). <https://doi.org/10.1007/s13205-022-03154-x>

16. Monoclonal Antibody Against Sortilin Induces Apoptosis in Human Breast Cancer Cells. Miganoosh Simonian, Mozhan Haji Ghaffari, Ali Salimi, Ebrahim Mirzadegan, Niloufar Sadeghi, Nasim Ebrahimnezhad, Ghazaleh Fazli, Ramina Fatemi, Ali-Ahmad Bayat, Saeideh Milani, Babak Negahdari, and **Hodjattallah Rabbani**. Avicenna J Med Biotech 2022; 14(1): 37-45

17. Monoclonal Antibody Against ROR1 Induces Apoptosis in Human Bladder Carcinoma Cells Ali-Ahmad Bayat, Niloufar Sadeghi, Ramina Fatemi, Mohammad Reza Nowroozi, Solmaz Ohadian Moghadam, Mohadeseh Borzuee, Amin Radmanesh, Mahmood Khodadoost, Ali Reza Sarrafzadeh, Omid Zarei, **Hodjattallah Rabbani** Avicenna J Med Biotechnol. 2020 Jul-Sep; 12(3): 165–171. PMID: PMC7368111
18. Taheri-Ledari R, Maleki A, Zolfaghari E, Radmanesh M, **Rabbani H**, Salimi A, Fazel R. High-performance sono/nano-catalytic system: Fe₃O₄@Pd/CaCO₃-DTT core/shell nanostructures, a suitable alternative for traditional reducing agents for antibodies. Ultrason Sonochem. 2020 Mar;61:104824. doi: 10.1016/j.ultsonch.2019.104824. Epub 2019 Oct 8.
19. Farahi L, Ghaemimanesh F, Milani S, Razavi SM, Bayat AA, **Rabbani H**, Akhondi MM. Monoclonal and Polyclonal Antibodies Specific to Human Fibromodulin. Iran J Biotechnol. 2019 Jan 11;17(1):e2277. doi: 10.21859/ijb.2277.
20. Shahmirzaie M¹, Safarnejad MR², Rakhshandehroo F¹, Safarpour H³, **Rabbani H**⁴, Zamanizadeh HR¹, Elbeaino T⁵. *Production of a polyclonal antiserum against recombinant nucleocapsid protein and its application for the detection of fig mosaic virus.* J Virol Methods. 2019 Mar;265:22-25
21. Ilanlou S, Khakbiz M, Amoabediny G, Mohammadi J, **Rabbani H**. Carboxymethyl kappa carrageenan-modified decellularized small-diameter vascular grafts improving thromboresistance properties. J Biomed Mater Res A. 2019 Aug;107(8):1690-1701. doi: 10.1002/jbm.a.36684. Epub 2019 Apr 29.
22. Farahi L, Ghaemimanesh F, Milani S, Razavi SM, Akhondi MM, **Rabbani H**. Sortilin as a Novel Diagnostic and Therapeutic Biomarker in Chronic Lymphocytic Leukemia. Avicenna J Med Biotechnol. 2019 Oct-Dec;11(4):270-276.
23. Farahi L, Ghaemimanesh F, Milani S, Razavi SM, Hadavi R, Bayat AA, Salimi A, Akhondi MM, **Rabbani H**. Anchored Fibromodulin as a Novel Target in Chronic Lymphocytic Leukemia: Diagnostic and Therapeutic Implications. Iran J Immunol. 2019 Jun;16(2):127-141. doi: 10.22034/IJI.2019.80256.
24. Hemmati A, Hassannia H, Milani S, Hadavi R, Ghaemimanesh F, **Rabbani H**. *Detecting Receptor Tyrosine Kinase ROR1 Using a Developed Anti-ROR1 Polyclonal Antibody.* Monoclon Antib Immunodiagn Immunother. 2018 Feb;37(1):38-44.
25. Saeideh Milani, Fatemeh Ghaemimenes, Ali Salimi, Reza Hadavi, Ali Ahmad Bayat, Behrouz Alirezapour, **Hodjattallah Rabbani**. *Production and evaluation of a 67Ga-labeled anti-Ror1 monoclonal antibody in a mouse model of breast cancer.* 2018, Journal of Radioanalytical and Nuclear Chemistry 316(1)
26. Nazila Amini, Ali-Ahmad Bayat, Omid Zarei, Reza Hadavi, Jafar Mahmoudian, Ahmad R. Mahmoudi, Maryam Darzi, **Hodjattallah Rabbani** and Mahmood Jeddi-Tehrani. A

- Novel Monoclonal Antibody Against a Synthetic Peptide from β -Actin can React with its Corresponding Protein.* Protein & Peptide Letters, 2015, 22(5), 419-24.
27. Hojjat-Farsangi M, Jeddi-Tehrani M, Daneshmanesh AH, Mozaffari F, Moshfegh A, Hansson L, Razavi SM, Sharifian RA, **Hodjattallah R**, Österborg A, Mellstedt H, Shokri F. *Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.* PLoS One. 2015;10(11).
28. Ghaemimanesh F, Bayat AA, Sepideh B, Ahmadian Gh, Zarnani AH, Behmanesh M, Jeddi-Tehrani M, **Rabbani H**. *Production and Characterization of a Novel Monoclonal Antibody Against Human Sortilin.* Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34(6):390-5.
29. Hossein Asgarian-Omran, Ali Akbar Amirzargar, Sacha Zeerleder, Marzieh Mahdavi, Gerard van erlo, Shabnam Solati, Mahmood Jeddi-Tehrani, **Rabbani H**, Leucien Aarden and Fazel Shokri. *Interaction of Bordetella pertussis filamentous hemagglutinin with human TLR2: identification of the TLR2-binding domain.* APMIS, Volume 123, Issue 2, pages 156–162, February 2015.
30. Nazila Amini, Mohadeseh Naghi Vishteh, Omid Zarei, Reza Hadavi, Negah Ahmadvand, **Hodjattallah Rabbani** and Mahmood Jeddi-Tehrani. *Production and characterization of polyclonal antibody against a synthetic peptide from β -actin protein.* Iranian Journal of Basic Medical Sciences, Vol. 17, No. 6, Jun 2014.
31. Fatemeh Ghaemimanesh, Gholamreza Ahmadian, Saeed Talebi, Amir-Hassan Zarnani, Mehrdad Behmanesh, Shayda Hemmati, Reza Hadavi, Mahmood Jeddi-Tehrani, Maryam Farzi, Mohammad Mehdi Akhondi and **Hodjattallah Rabbani**. *The effect of sortilin silencing on ovarian carcinoma cells.* Avicenna Journal of Medical Biotechnology, Vol. 6, No. 3, July-September 2014.
32. Mehdi Yousefi, Fathollah Tahmasebi, Vahid Younesi, Alireza Razavi, Jalal Khoshnoodi, Ali Ahmad Bayat, Ebrahim Abbasi, **Hodjatallah Rabbani**, Mahmood Jeddi-Tehrani & Fazel Shokri. *Characterization of neutralizing monoclonal antibodies directed against tetanus toxin fragment C.* Journal of Immunotoxicology, Volume 11, Issue 1, 2014 Jan-Mar.
33. Mehdi Yousefi, Roya Khosravi-eghbal, ahmad Reza Mahmoudi, Mahmood Jeddi-Tehrani, **Hodjatallah Rabbani** and Fazel shokri. *Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies.* Hum Vaccin Immunother. 2014 Feb 1; Volume 10, Issue 2.
34. Forough Golsaz Shirazi, Hamed Mohammadi, Mohammad Mehdi Amiri, Katrin Singethan, Yuchen Xia, Ali Ahmad Bayat, Motahareh Bahadori, **Hodjatallah Rabbani**, Mahmood Jeddi-Tehrani, Ulrike Protzer and Fazel Shokri. *Monoclonal antibodies to various epitopes of hepatitis B surface antigen inhibit hepatitis B virus infection.* Journal of Gastroenterology and Hepatology, Volume 29, Issue 5, pages 1083–1091, May 2014.
35. Fathollah Tahmasebi, Tohid Kazemi, Mohammad Mehdi Amiri, Jalal Khoshnoodi, Jafar Mahmoudian, Ali Ahmad Bayat, Mahmood Jeddi-Tehrani, **Hodjatallah Rabbani** & Fazel Shokri. *In vitro assessment of the effects of anti-HER2 monoclonal antibodies on*

proliferation of HER2-overexpressing breast cancer cells. Immunotherapy, January 2014 ,Vol. 6, No. 1, Pages 43-49 , DOI 10.2217/imt.13.156.

36. Mahdi Shabani, Ali Ahmad Bayat, Mahmood Jeddi-Tehrani, **Hodjatallah Rabbani**, Mohammad Hojjat-Farsangi, Cristina Ulivieri, Zahra Amirghofran, Cosima Tatiana Baldari and Fazel Shokri. *Ligation of human Fc receptor like-2 by monoclonal antibodies down-regulates B-cell receptor-mediated signaling*. Immunology, Volume 143, Issue 3, pages 341–353, November 2014.
37. Gharaati M.R., Mirshahi M., **Rabbani H.**, Saifi-Abolhassan M., Behmanesh M. and Shamsi Poor F. *Cloning and expression of a scFv from an anti human plasminogen monoclonal antibody*. Iranian Journal of Biology, Volume 26, Issue 1, Spring 2013, Page 52-60.
38. Amir Hossein Daneshmanesh, Anna Porwit, Mohammad Hojjat-Farsangi, Mahmood Jeddi-Tehrani, Katja Pokrovskaja Tamm, Dan Grandér, Sören Lehmann, Stefan Norin, Fazel Shokri, **Hodjattallah Rabbani**, Håkan Mellstedt & Anders Österborg. *Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies*. Leukemia & Lymphoma, Volume 54, Issue 4, 2013 Apr.
39. Eva Mikaelsson, Anders Österborg, Mahmood Jeddi-Tehrani, Parviz Kokhaei, Mahyar Ostadkarampour, Reza Hadavi, Mehran Gholamin, Mehdi Akhondi, Fazel Shokri, **Hodjattallah Rabbani** and Håkan Mellstedt. *A Proline/Arginine-Rich End Leucine-Rich Repeat Protein (PRELP) Variant Is Uniquely Expressed in Chronic Lymphocytic Leukemia Cells*. PLoS One. June 2013 | Volume 8 | Issue 6.
40. Eva Mikaelsson, Anders Österborg, Zahra Tahmasebi Fard, Ahmad Mahmoudi, Jafar Mahmoudian, Mahmood Jeddi-Tehrani, Mehdi Akhondi, Fazel Shokri, Paul N Bishop, **Hodjattallah Rabbani** and Håkan Mellstedt. *Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells*. Experimental Hematology & Oncology, 28 August 2013, Volume 2; 2013.
41. Ghasem Ghalamfarsa, Farhad Jadidi-Niaragh, Mohammad Hojjat-Farsangi, Hossein Asgarian-Omran, Mehdi Yousefi, Fathollah Tahmasebi, Jalal Khoshnoodi, Seyed Mohsen Razavi, Ali Akbar Saboor-Yaraghi, **Hodjatallah Rabbani**, Mahmood Jeddi-Tehrani, Fazel Shokri. *Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia*. Cytokine, Volume 62, Issue 3, June 2013, Pages 439–445.
42. Mohammad Hojjat-Farsangi, Fatemeh Ghaemimanesh, Amir Hossein Daneshmanesh, Ali-Ahmad Bayat, Jafar Mahmoudian, Mahmood Jeddi-Tehrani, **Hodjatallah Rabbani** and Hakan Mellstedt. *Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells*. PLOS ONE, April 2013, Volume 8, Issue 4.
43. Hossein Asgarian-Omran, Ali Akbar Amirzargar, Mohammad Arjmand, Mohammadreza Eshraghian, Behrooz Nikbin, Saeid Eshraghi, Marzieh Mahdavi, Jalal Khoshnoodi, Mahmood Jeddi-Tehrani, **Hodjatallah Rabbani** and Fazel Shokri. *Expression, Purification and Characterization of Three Overlapping Immunodominant Recombinant Fragments from Bordetella pertussis Filamentous Hemagglutinin*. Avicenna Journal of Medical Biotechnology, Vol. 5, No. 1, January-March 2013.

44. Mohammad Mehdi Amiri, Mahmood Jeddi-Tehrani, Tohid Kazemi, Motahareh Bahadori, Mahshid Maddah, Mohammad Hojjat-Farsangi, Jalal Khoshnoodi, **Hodjattallah Rabbani** & Fazel Shokri. *Construction and characterization of a new chimeric antibody against HER2*. Immunotherapy, July 2013 ,Vol. 5, No. 7, Pages 703-715 , DOI 10.2217/imt.13.67.
45. Mahdi Shabani, Azam Hemmati, Mahdi Zandemami, Jalal Khoshnoodi, Mahmood Jeddi-Tehrani, **Hodjattallah Rabbani**, Zahra Amirghofran, Fazel Shokri. *Cloning, Expression and Characterization of Recombinant Human Fc Receptor Like 1, 2 and 4 Molecules*. Iranian Journal of Biotechnology, Volume 11, Issue 3, Summer 2013, Page 182-192.
46. Mohadeseh Naghi Vishteh, Seyyed Javad Seyyed-Tabaei, Ali Haghighi, Amir Hassan Zarnani, Nazila Amini, Omid Zarei, Reza Hadavi, **Hodjattallah Rabbani** and Mahmood Jeddi-Tehrani. *Peptide-based polyclonal antibody production against SAG1 (P30) protein of Toxoplasma gondii*. Annals of Biological Research, 2012, 3 (7):3577-3582.
47. A H Daneshmanesh, M Hojjat-Farsangi, A S Khan, M Jeddi-Tehrani, M M Akhondi, A A Bayat, R Ghods, A-R Mahmoudi, R Hadavi, A Österborg, F Shokri, **H Rabbani** and H Mellstedt. *Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells*. Leukemia, 26, 1348-1355 (June 2012)| doi:10.1038/leu.2011.362.
48. Likun Du, Roujun Peng, Andrea Björkman, Noel Filipe de Miranda, Cornelia Rosner, Ashwin Kotnis, Mattias Berglund, Chonghai Liu, Richard Rosenquist, Gunilla Enblad, Christer Sundström, Mohammad Hojjat-Farsangi, **Hodjattallah Rabbani**, Manuel R. Teixeira, Patrick Revy, Anne Durandy, Yixin Zeng, Andrew R. Gennery, Jean-Pierre de Villartay and Qiang Pan-Hammarström. *Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis*. The Journal of Experimental Medicine, 2012 Feb 13; 209(2): 291–305.
49. Sheila Sarial, Farzad Asadi, Mahmood Jeddi-Tehrani, Reza Hadavi, Ali Ahmad Bayat, Jafar Mahmoudian, Masoud Taghizadeh-Jahed, Fazel Shokri, and **Hodjattallah Rabbani**. *A High Affinity Monoclonal Antibody Recognizing the Light Chain of Human Coagulating Factor VII*. Hybridoma, Volume: 31 Issue 6: December 17, 2012.
50. Flora Forouzesheh, Samira Shakeri Tabarian, Shaghayegh Emami, Mahmood-Jeddi Tehrani, Reza Hadavi and **Hodjattallah Rabbani**. *Construction and Stable Expression of a Truncated Human Receptor Tyrosine Kinase Ror1 (Ror1-ECD)*. Avicenna Journal of Medical Biotechnology, Vol. 4, No. 1, January-March 2012.
51. Ahmad Reza Mahmoudi, Elham Shaban, Roya Ghods, Mahmood Jeddi-Tehrani, Shaghayegh Emami, **Hodjattallah Rabbani**, Amir Hassan Zarnani & Jafar Mahmoudian. *Comparison of Photostability and Photobleaching Properties of FITC- and Dylight488-Conjugated Herceptin*. International Journal of Green Nanotechnology, Volume 3, Issue 4, 2011.
52. Mahdi Shabani, Hossein Asgarian Omran, Mohammad Hojjat Farsangi, Parvaneh Vossough, Ramazan A. Sharifian, Gholam R. Toughe, Seyed Mohsen Razavi, Jalal Khoshnoodi, Mahmood Jeddi-Tehrani, **Hodjattallah Rabbani** and Fazel Shokri. *Comparative Expression Profile of Orphan Receptor Tyrosine Kinase ROR1 in Iranian*

- Patients with Lymphoid and Myeloid Leukemias*. Avicenna Journal of Medical Biotechnolog, Vol. 3, No. 3, July-September 2011.
53. Tohid Kazemi, Fathollah Tahmasebi, Ali Ahmad Bayat, Neda Mohajer, Jalal Khoshnoodi, Mahmood Jeddi-Tehrani, **Hodjattallah Rabbani** and Fazel Shokri. *Characterization of novel murine monoclonal antibodies directed against the extracellular domain of human HER2 tyrosine kinase receptor*. Hybridoma. Volume: 30 Issue 4: August 18, 2011.
54. Davide Bagnara, Matthew S. Kaufman, Carlo Calissano, Sonia Marsilio, Piers E. M. Patten, Rita Simone, Philip Chum, Xiao-Jie Yan, Steven L. Allen, Jonathan E. Kolitz, Sivasubramanian Baskar, Christoph Rader, Hakan Mellstedt, **Hodjattallah Rabbani**, Annette Lee, Peter K. Gregersen, Kanti R. Rai, and Nicholas Chiorazzi. *A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease*. Blood. 2011 May 19;117(20).
55. Omid Zarei, Gholam Reza Irajian, Amir Hassan Zarnani, Leili Chamani-Tabriz, Shaghayegh Emami, Mahmood Jeddi-Tehrani and **Hodjattallah Rabbani**. *Peptide-based Polyclonal Antibody Production against P110 Protein of Mycoplasma genitalium*. Avicenna Journal of Medical Biotechnolog, Vol. 3, No. 2, April-June 2011.
56. Mona Noori Koopaei, rassoul Dinarvand, Mohsen Amini, **Hodjattallah Rabbani**, shaghayegh emami, seyed Nasser Ostad, Fatemeh Atyabi. *Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies*. International Journal of Nanomedicine, Volume 6; 2011.
57. Zahra Tahmasebi Fard, Kazem Parivar, **Hodjattallah Rabbani**, Mahmoud Jeddi Tehrani, Sheida Hemmati. *Analysis of gene and protein expression of opticin in human cancer cell lines*. Medical Sciences Journal of Islamic Azad University, Tehran Medical Branch, Volume 20, Number 2 (2010).
58. Amir Hassan Zarnani, Mehdi Shahbazi, Alireza Salek-Moghaddam, Mehri Zareie, Maryam Tavakoli, Jemileh Ghasemi, Simin Rezania, Ali Moravej, Ebrahim Torkabadi, **Hodjattallah Rabbani**, Mahmood Jeddi-Tehrani. *Vitamin D₃ receptor is expressed in the endometrium of cycling mice throughout the estrous cycle*. Fertility and Sterility, May 15, 2010, Volume 93, Issue 8, Pages 2738–2743.
59. **Hodjattallah Rabbani**, Mahyar Ostadkarampour, Amir Hossein Danesh Manesh, Abbas Basiri, Mahmood Jeddi-Tehrani, Flora Forouzesh. *Expression of ROR1 in Patients with Renal Cancer-A Potential Diagnostic Marker*. Iranian Biomedical Journal, Volume 14, Number 3 (2010).
60. Jafar Mahmoudian, Mahmood Jeddi-Tehrani, **Hodjattallah Rabbani**, Ahmad Reza Mahmoudi, Mohammad Mehdi Akhondi, Amir Hassan Zarnani, Leila Balaei Goli, Mahdokht Babaei and Roya Ghods. *Conjugation of R-Phycoerythrin to a Polyclonal Antibody and F (ab')₂ Fragment of a Polyclonal Antibody by Two Different Methods*. Avicenna Journal of Medical Biotechnology, Vol. 2, No. 2, April- June 2010.
61. Reza Hadavi, Amir Hassan Zarnani, Negah Ahmadvand, Ahmad Reza Mahmoudi, Ali Ahmad Bayat, Jafar Mahmoudian, Mohammad-Reza Sadeghi, Haleh Soltanghoreae,

- Mohammad Mehdi Akhondi, Majid Tarahomi, Mahmood Jeddi-Tehrani and **Hodjattallah Rabbani**. *Production of Monoclonal Antibody against Human Nestin*. Avicenna Journal of Medical Biotechnology, Vol. 2, No. 2, April- June 2010.
62. Vahid Younesi, Haleh Nikzamir, Mehdi Yousefi, Jalal Khoshnoodi, Mohammad Arjmand, **Hodjatallah Rabbani** and Fazel Shokri. *Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B lymphocytes*. Microbiology and Immunology, Volume 54, Issue 9, pages 534–541, September 2010.
63. Ali Moravej, Mahmood Jeddi-Tehrani, Ali R. Salek-Moghaddam, Pouneh Dokouhaki, Roya Ghods, **Hodjatallah Rabbani**, Golnaz E. Kazemi-Sefat, Mehdi Shahbazi and Amir H. Zarnani. *Evaluation of thyroglobulin expression in murine reproductive organs during pregnancy*. American Journal of Reproductive Immunology, Volume 64, Issue 2, pages 97–103, August 2010.
64. Mahdi Shabani, Sheyda Hemmati, Reza Hadavi, Zahra Amirghofran, Mahmood Jeddi-Tehrani, **Hodjatallah Rabbani** and Fazel Shokri. *Optimization of Gene Transfection in Murine Myeloma Cell Lines using Different Transfection Reagents*. Avicenna Journal of Medical Biotechnology. Vol. 2, No. 3, July- September 2010.
65. Hossein Asgarian-Omran, Parvin Forghani, Mohammad Hojjat-Farsangi, Azam Roohi, Ramazan Ali Sharifian, Seyed Mohsen Razavi, Mahmood Jeddi-Tehrani, **Hodjatallah Rabbani** & Fazel Shokri. *Expression profile of galectin-1 and galectin-3 molecules in different subtypes of chronic lymphocytic leukemia*. Cancer Investigation, Volume 28, Issue 7, 2010.
66. Mohammad Mehdi Akhondi, Reza Akbarzadeh Najar, Mahmood Jeddi-Tehrani, Mohammad-Reza Sadeghi, Amir Hassan Zarnani, **Hodjattallah Rabbani**, Sheida Salehkhoh, Leila Eini, Fatemeh Hoseinzadeh and Mahnaz Heidari. *The Effect of Human Chorionic Gonadotropin Treatment on Recipient Mouse Germ Cell Proliferation Following Spermatogonial Stem Cell Transplantation of Neonatal Donor Mice*. Avicenna Journal of Medical Biotechnology, Vol. 2, No. 1, January-March 2010.
67. Leila Barzegar Yarmohammadi, Mohammad Hossein Modarresi, Saeed Talebi, Reza Hadavi, Mahyar Ostad Karampour, Ahmad Reza Mahmoudi, Mohammad Mehdi Akhondi, **Hodjattallah Rabbani**, Mahmood Jeddi-Tehrani. *Producing Recombinant mTEX101; a Murine Testis Specific Protein*. Journal of Reproduction and Infertility, Volume 10, Issue 3, Number 40 / October-December 2009.
68. Shayda Hemmati, Amir Hassan Zarnani, Ahmad Reza Mahmoudi, Mohammad-Reza Sadeghi, Haleh Soltanghoreae, Mohammad Mehdi Akhondi, Majid Tarahomi, Mahmood Jeddi-Tehrani and **Hodjattallah Rabbani**. *Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma*. Avicenna Journal of Medical Biotechnology, Vol. 1, No. 2, July-September 2009.
69. Yaofeng Zhao, Zhancai Liu, Shuyang Yu, Sicheng Wen, Lennart Hammarstrom and **Hodjattallah Rabbani**. *Construction of a High Efficiency PCR Products Cloning T Vector Using pGEM-5zf (+)*. Avicenna Journal of Medical Biotechnology, Vol. 1, No. 1, April- June 2009.

70. Fatemi F, Chamani L, Pakzad P, Zeraati H, **Rabbani H**, Asgari S. *Colonization Rate of Group B Streptococcus (GBS) in Pregnant Women Using GBS Agar Medium*. Acta Medica Iranica, 2009. 47(1):25-30.
71. M. Jeddi-Tehrani, N. Abbasi, P. Dokouhaki, J. Ghasemi, S. Rezaia, M. Ostadkarampour, **H. Rabbani**, M.A. Akhondi, Z. Tahmasebi Fard, A.H. Zarnani. *Indoleamine 2,3-dioxygenase is expressed in the endometrium of cycling mice throughout the oestrous cycle*. Journal of Reproductive Immunology, June 2009, Volume 80, Issues 1-2, Pages 41–48.
72. Tohid Kazemi, Hossein Asgarian-Omran, Ali Memarian, Mahdi Shabani, Ramazan A. Sharifian, Parvaneh Vossough, Bita Ansaripour, **Hodjatallah Rabbani**, Fazel Shokri. *Low representation of Fc receptor-like 1–5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia*. Cancer Immunol Immunother. 2009 Jun;58(6):989-96.
73. Mohammad Hojjat-Farsangi, Mahmood Jeddi-Tehrani, Seyed Mohsen Razavi, Ramazan Ali Sharifian, Hakan Mellstedt, Fazel Shokri and **Hodjatallah Rabbani**. *Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia*. Cancer Science, Volume 100, Issue 12, pages 2346–2353, December 2009
74. Ali Memarian, Mohammad Hojjat-Farsangi, Hossein Asgarian-Omran, Vahid Younesi, Mahmood Jeddi-Tehrani, Ramazan Ali Sharifian, Jalal Khoshnoodi, Seyed Mohsen Razavi, **Hodjatallah Rabbani** & Fazel Shokri. *Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia*. Leukemia & Lymphoma, Volume 50, Issue 12, 2009.
75. Hassan Vahidnezhad, Leila Youssefian, Mahmoud Jeddi-Tehrani, Mohammad Mehdi Akhondi, **Hodjatallah Rabbani**, Fazel Shokri, Mina Tabrizi. *Modeling Breast Acini in Tissue Culture for Detection of Malignant Phenotype Reversion to Non-Malignant Phenotype*. Iranian Biomedical Journal, Volume 13, Number 4, 2009 Oct.
76. Chamani-Tabriz L, Tehrani M, Zeraati H, Asgari S, Moini M, **Rabbani H**, Mamani M. *Molecular Survey on Prevalence of Chlamydia trachomatis Infection in Pregnant Woman Attending OB&GY Clinics of Tehran*. Iranian Journal of Infectious Diseases and Tropical Medicine, 2008, Vol 13, Issue 41, Page: 45-50.
77. Amir H. DaneshManesh, Eva Mikaelsson, Mahmood Jeddi-Tehrani, Ali Ahmad Bayat, Roya Ghods, Mahyar Ostadkarampour, Mehdi Akhondi, Svetlana Lagercrantz, Catharina Larsson, Anders Österborg, Fazel Shokri, Håkan Mellstedt and **Hodjatallah Rabbani**. *Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy*. International Journal of Cancer, Volume 123, Issue 5, pages 1190–1195, 1 September 2008.
78. Hossein Asgarian Omran, Mahdi Shabani, Parvaneh Vossough, Ramazan Sharifian, Mina Tabrizi, Jalal Khoshnoodi, Mahmood Jeddi-Tehrani, **Hodjatallah Rabbani** & Fazel Shokri. *Cross-sectional monitoring of Wilms' tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission*. Leukemia & Lymphoma, Volume 49, Issue 2, 2008.

79. Mohammad Hojjat Farsangi, Mahmoud Jeddi-Tehrani, Seyed Mohsen Razavi, Ramazan Ali Sharifian, Ahmad Shamsian Khoramabadi, **Hodjatollah Rabbani**, Fazel Shokri. *Immunophenotypic Characterization of the Leukemic B-cells from Iranian Patients with Chronic Lymphocytic Leukemia: Association between CD38 Expression and Disease Progression*. Iranian Journal of Immunology. Vol. 5 No. 1 March 2008
80. Mahdi Shabani, Hossein Asgarian-Omran, Parvaneh Vossough, Ramazan A. Sharifian, Mohammad Faranoush, Soheila Ghragozlou, Jalal Khoshnoodi, Azam Roohi, Mahmoud Jeddi-Tehrani, Hakan Mellstedt, **Hodjatallah Rabbani** & Fazel Shokri. *Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia*. Leukemia & Lymphoma, Volume 49, Issue 7, 2008.
81. Tohid Kazemi, Hossein Asgarian-Omran, Mohammad Hojjat-Farsangi, Mahdi Shabani, Ali Memarian, Ramazan Ali Sharifian, Seyed Mohsen Razavi, Mahmoud Jeddi-Tehrani, **Hodjatallah Rabbani** and Fazel Shokri. *Fc receptor-like 1–5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia*. International Journal of Cancer, Volume 123, Issue 9, pages 2113–2119, 1 November 2008.
82. Mohsen Meidani, Leili Chamani Tabriz, Hojjat Zeraati, Bahram Razin, Bahareh Jamali, Latif Gachkar, Soheila Asgari, **Hodjatallah Rabbani**, Mahyar Ostad Karampour. *Molecular Assessment on The Prevalence of Urogenital Infection with Chlamydia Trachomatis in Asymptomatic Men*. Journal of Isfahan Medical School, 2008; 25(87): 45-51.
83. Mohammad Hojjat-Farsangi, Mahmoud Jeddi-Tehrani, Ali Akbar Amirzargar, Seyed Mohsen Razavi, Ramazan Ali Sharifian, **Hodjatallah Rabbani**, Fazel Shokri. *Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia*. Human Immunology, Volume 69, Issue 10, October 2008, Pages 666–674.
84. M. Hojjat Farsangi, M. Jeddi-Tehrani, R. A. Sharifian, S. M. Razavi, J. Khoshnoodi, **H. Rabbani** & Dr F. Shokri. *Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chronic lymphocytic leukemia*. Leukemia & Lymphoma, Volume 48, Issue 1, 2007.
85. Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M, Sharifian RA, Touge GR, Kordmahin M, Khoshnoodi J, Roohi A, Tavoosi N, Mellstedt H, **Rabbani H**, Shokri F. *Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia*. Tumour Biol. 2007;28(6):318-26.
86. Asgarian Omran H, Shabani M, Shahrestani T, Sarafnejad A, Khoshnoodi J, Vossough P, Faranoush M, Sharifian RA, Jeddi-Tehrani M, **Rabbani H**, Shokri F. *Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome*. Iran J Immunol. 2007 Mar;4(1):15-25.

87. Memarian A, Jeddi Tehrani M, Vossough P, Sharifian RA, **Rabbani H**, Shokri F. *Expression profile of Wnt molecules in leukemic cells from Iranian patients with acute myeloblastic leukemia*. Iran J Immunol. 2007 Sep;4(3):145-54
88. Mohammad Reza Rezvany, Mahmood Jeddi Tehrani, Claes Karlsson, Jeanette Lundin, **Hodjattallah Rabbani**, Anders Österborg and Håkan Mellstedt. *Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia*. British Journal of Haematology, Volume 135, Issue 4, pages 475–485, November 2006.
89. Farah Idali, Maria Wikén Jan Wahlström Håkan Mellstedt Anders Eklund, **Hodjattallah Rabbani** and Johan Grunewald. *Reduced Th1 response in the lungs of HLA-DR17 positive patients with pulmonary sarcoidosis*. Eur Respir J. 2006 Mar;27(3):451-9.
90. Leili Chamani Tabriz, Mahmood Jeddi-Tehrani, Alireza Mosavi-Jarrahi, Hojjat Zeraati, Jamileh Ghasemi, Soheila Asgari, **Hodjattallah Rabbani**, Mojgan Mamani. *The prevalence of Chlamydia trachomatis infection by molecular analysis of urine samples in women attending OB & GYN clinics in Tehran*. Journal of Reproduction & Infertility, Volume 7, Issue 3, Number 28 / October-December 2006.
91. Hossein Asgarian, Mahdi Shabani, Parvaneh Vosoogh, Ramezan Ali Sharifian, Soheila Ghragozlou, Jalal Khoshnoodi, Tahereh Shahrestani, Mahin Kordmahin, Abdolfattah Sarafnejad, Mahmood JeddiTehrani, **Hodjatollah Rabbani**, Fazel Shokri. *Over-expression of Wilm's Tumor Gene 1 (WT1) in Iranian Patients with Acute Myeloblastic Leukemia*. Iranian Journal of Immunology, Vol. 2 No. 4 Autumn 2005.
92. Soheila Gharagozlou, Gholam Ali Kardar, **Hodjattallah Rabbani**, Fazel Shokri. *Molecular analysis of the heavy chain variable region genes of human hybridoma clones specific for coagulation factor VIII*. Thrombosis and Haemostasis, 2005: 94(6) (Dec) pp. 1116-1344.
93. Chromek, M. Stankowska, D. Dadfar, E. Kaca, W. **Rabbani, H.** Brauner, A. *Interleukin-8 Response In Cells From The Human Urinary Tract Induced By Lipopolysaccharides Of Proteus Mirabilis O3 And O18*. J Urol, 2005, 173, 4, 1381-1384.
94. Eva Mikaelsson, Amir Hossein Danesh Manesh, Alfred Lüppert, Mahmood Jeddi- Tehrani, Mohammad-Reza Rezvany, Ramazan Ali Sharifian, Reza Safaie, Azam Roohi, Anders Österborg, Håkan Mellstedt, Fazel Shokri and **Hodjattallah Rabbani**. *Fibromodulin - an Extracellular Matrix Protein: Characterization of its Unique Gene and Protein Expression in B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Mantle Cell Lymphoma*. Blood, 2005, 105, 12, 4828-35
95. Hansson M, Djerbi M, **Rabbani H**, Mellstedt H, Gharibdoost F, Hassan M, Depierre JW, Abedi-Valugerdi M. *Exposure to mercuric chloride during the induction phase and after the onset of collagen-induced arthritis enhances immune/autoimmune responses and exacerbates the disease in DBA/1 mice*. Immunology, 2005, 114, 428–437
96. Mozaffari, F. Hansson, L. Kiaii, S. Ju, X. Rossmann, E. D. **Rabbani, H.** Mellstedt, H. Osterborg, A. *Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage*. Br J Haematol. 2004, 124, 3, 315-324

97. Zhao Y, Pan Q, **Rabbani H**, Hammarström L. *Characterization of the cattle immunoglobulin heavy chain constant region gene locus*. J. Biol. Chem. 2003;278, 37, 35024-32
98. Ullenhag GJ, Frodin JE, Mosolits S, Kiaii S, Hassan M, Bonnet M, Moingeon P, Mellstedt H, **Rabbani H**. *Immunization of colorectal carcinoma patients with a recombinant canary pox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and GM-CSF induced a tumor-specific cellular immune response*. Clin Can Res. 2003;9, 7, 2447-56
99. Osman Abdalla A, Kiaii S, Hansson L, Rosmann-Dohany E, Jeddi-Tehrani M, Osterborg A, Mellstedt H, **Rabbani H**. *Kinetics of cytokine gene expression in human CD4+ and CD8+ T lymphocyte subsets using quantitative Real-Time PCR*. Scand J Immunol. 2003;58, 6, 601-6
100. Kokhaei P, Rezvany R, Virving L, Choudhury A, **Rabbani H**, Osterborg A, Mellstedt H. *Dendritic cells loaded with apoptotic tumour cells induce a stronger T cell response than dendritic cell-tumour hybrids in B-CLL*. Leukemia. 2003;17, 5, 894-9
101. Kiaii S, Jeddi-Tehrani M, Osterborg A, Mellstedt H, **Rabbani H**. *Utilizing ki67 gene expression for monitoring T cell activation*. Immunological methods. 2004;Submitted
102. Hansson L, **Rabbani H**, Fagerberg J, Osterborg A, Mellstedt H. *T-cell epitopes within the complementarity-determining and framework regions of the tumor derived immunoglobulin heavy chain in multiple myeloma*. Blood. 2003;101, 12, 4930-6
103. Gharagozlou S, Ghods R, Samadi Bahrami Z, Roohi A, Jeddi-Tehrani M, Conti-Fine BM, Sharifian RA, **Rabbani H**, Shokri F. *Characterization of Human Hybridoma Clones Isolated From Hemophilia Patients with Specificity for Different Domains of Coagulating Factor VIII*. Hum Antibodies. 2003;12, 3, 67-76.
104. Zhao Y, Kacs Kovics I, Pan Q, Liberles DA, Geli J, Davis SK, **Rabbani H**, Hammarstrom L. *Artiodactyl IgD: the missing link*. J Immunol. 2002;169:4408-4416.
105. Roether S, **Rabbani H**, Mellstedt H, Abedi-Valugerdi M. *Spontaneous downregulation of antibody/autoantibody synthesis in susceptible mice upon chronic exposure to mercuric chloride is not owing to a general immunosuppression*. Scand J Immunol. 2002;55:493-502.
106. Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, **Rabbani H**, Kalantari M, Dalianis T. *Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer*. Int J Cancer. 2002;102:152-158.
107. Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, **Rabbani H**, Moretta A, Soderstrom K, Levitskaya J, Kiessling R. *IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism*. J Clin Invest. 2002;110:1515-1523
108. Islam TC, Lindvall J, Wennborg A, Branden LJ, **Rabbani H**, Smith CI. *Expression profiling in transformed human B cells: influence of Btk mutations and comparison to B*

- cell lymphomas using filter and oligonucleotide arrays.* Eur J Immunol. 2002 Apr;32(4):982-93.
109. Rezvany MR, Jeddi-Tehrani M, Biberfeld P, Soderlund J, Mellstedt H, Osterborg A, **Rabbani H**. *Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern.* Br J Haematol. 2001;115:263-271
110. Brenden N, **Rabbani H**, Abedi-Valugerdi M. *Analysis of mercury-induced immune activation in nonobese diabetic (NOD) mice.* Clin Exp Immunol. 2001;125:202-210
111. Zhao Y, **Rabbani H**, Shimizu A, Hammarstrom L. *Mapping of the chicken immunoglobulin heavy-chain constant region gene locus reveals an inverted alpha gene upstream of a condensed epsilon gene.* Immunology. 2000;101:348-353
112. Rezvany MR, Jeddi-Tehrani M, **Rabbani H**, Lewin N, Avila-Carino J, Osterborg A, Wigzell H, Mellstedt H. *Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia.* Br J Haematol. 2000;111:608-617
113. Rezvany MR, Jeddi-Tehrani M, **Rabbani H**, Ruden U, Hammarstrom L, Osterborg A, Wigzell H, Mellstedt H. *Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia.* Br J Haematol. 2000;111:230-238
114. Pan Q, **Rabbani H**, Hammarstrom L. *Characterization of human gamma 4 switch region polymorphisms suggests a meiotic recombinational hot spot within the Ig locus: influence of S region length on IgG4 production.* J Immunol. 1998;161:3520-3526
115. Mousavi M, **Rabbani H**, Pilstrom L, Hammarstrom L. *Characterization of the gene for the membrane and secretory form of the IgM heavy-chain constant region gene (C mu) of the cow (Bos taurus).* Immunology. 1998;93:581-588.
116. Luo L, Lu FM, Hart S, Foroni L, **Rabbani H**, Hammarstrom L, Yuille MR, Catovsky D, Webster AD, Vorechovsky I. *Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL.* Cancer Res. 1998;58:2293-2297.
117. **Rabbani H**, Brown WR, Butler JE, Hammarstrom L. *Polymorphism of the IGHG3 gene in cattle.* Immunogenetics. 1997;46:326-331.
118. Pan Q, **Rabbani H**, Mills FC, Severinson E, Hammarstrom L. *Allotype-associated variation in the human gamma3 switch region as a basis for differences in IgG3 production.* J Immunol. 1997;158:5849-5859.
119. Mousavi M, **Rabbani H**, Hammarstrom L. *Characterization of the bovine epsilon gene.* Immunology. 1997;92:369-373.
120. Brown WR, **Rabbani H**, Butler JE, Hammarstrom L. *Characterization of the bovine C alpha gene.* Immunology. 1997;91:1-6.

121. **Rabbani H**, Pan Q, Kondo N, Smith CI, Hammarstrom L. *Duplications and deletions of the human IGHC locus: evolutionary implications. Immunogenetics.* 1996;45:136-141.
122. Truedsson L, Baskin B, Pan Q, **Rabbani H**, Vorechovsky I, Smith CI, Hammarstrom L. *Genetics of IgA deficiency. Apmis.* 1995;103:833-842.
123. **Rabbani H**, Kondo N, Smith CI, Hammarstrom L. *The influence of gene deletions and duplications within the IGHC locus on serum immunoglobulin subclass levels. Clin Immunol Immunopathol.* 1995;76:S214-218.
124. Islam KB, **Rabbani H**, Larsson C, Sanders R, Smith CI. *Molecular cloning, characterization, and chromosomal localization of a human lymphoid tyrosine kinase related to murine Blk. J Immunol.* 1995;154:1265-1272.
125. Ahlin A, De Boer M, Roos D, Leusen J, Smith CI, Sundin U, **Rabbani H**, Palmblad J, Elinder G. *Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta Paediatr.* 1995;84:1386-1394.
126. Smith CI, Islam KB, Vorechovsky I, Olerup O, Wallin E, **Rabbani H**, Baskin B, Hammarstrom L. *X-linked agammaglobulinemia and other immunoglobulin deficiencies. Immunol Rev.* 1994;138:159-183.
127. **Rabbani H**, de Boer M, Ahlin A, Sundin U, Elinder G, Hammarstrom L, Palmblad J, Smith CI, Roos D. *A 40-base-pair duplication in the gp91-phox gene leading to X-linked chronic granulomatous disease. Eur J Haematol.* 1993;51:218-222.
128. **Rabbani H**, Bottaro A, Carbonara AO, Brusco A, Cariota U, Olsson PG, Smith CI, Hammarstrom L. *The influence of gene duplications in the human immunoglobulin heavy chain constant locus on serum levels of immunoglobulin. Immunodeficiency.* 1993;4:237-241.
129. Olsson PG, **Rabbani H**, Hammarstrom L, Smith CI. *Novel human immunoglobulin heavy chain constant region gene deletion haplotypes characterized by pulsed-field electrophoresis. Clin Exp Immunol.* 1993;94:84-90.

Abstracts

1. Niloufar Sadeghi, Parisa Javadi, Javad Mohammadi, **Hodjattallah Rabbani**. Cell Surface Nanog-a Novel Marker in Breast Cancer Targeted Immunotherapy. 15th Annual PEGS Europe. Lisbon Congress Center, Lisbon, Portugal, November 14th – 16th, **2023, POSTER**
2. Fatemeh Ghaemimanesh, Gholamreza Ahmadian, Amir-Hassan Zarnani, Mehrdad Behmanesh, Mahmood Jeddi-Tehrani, **Hodjattallah Rabbani**. *Down regulation of sortilin as an ovarian carcinoma biomarker induces apoptosis in ovarian carcinoma cells*. 8th Asian Pacific Organization for Cancer Prevention Regional Conference, November 1-3, 2015, Tehran, Iran (Poster).
3. Amiri M-M, Shokri F, Jeddi-Tehrani M, Bahadori M, Farid S, Khoshnoodi J, Karimi-Jafari M-H, **Rabbani H**. *development of a new anti Her-2 humanized monoclonal antibody with enhanced effector function*. 7th Breast Cancer Congress, October 22-24, 2014 (Oral).
4. Emami S, Shabani M, Shakeri S, Hadavi R, Khosravi F, Hassannia H, Mahmoudi AR, Balaie-goli L, Bayat AA, Akbari ME, Jeddi-Tehrani M, Shokri F and **Rabbani H**. *A new murine monoclonal antibody for screening of human epidermal growth factor receptor-2 (HER2) in breast cancer patients*. 12th International Congress of Immunology & Allergy of Iran, April 29, 2014 – May 2, 2014, Tehran-Iran (Poster).
5. Shabani M, Hemmati A, Mahmoudian J, Bayat A.A, Jeddi-Tehrani M, **Rabbani H**, Ulivieric C, Amirghofran Z, Baldari CT, Shokri F. *ligation of human Fc receptor like 4 (FCRL4) by specific monoclonal antibodies down-regulates B cell receptor mediated signaling*. 12th International Congress of Immunology & Allergy of Iran, April 29, 2014 – May 2, 2014, Tehran-Iran (Oral).
6. Golsaz Shirazi F, Mohammadi H, Amiri MM, Singethan K, Xia Y, Bayat AA, Bahadori M, **Rabbani H**, Jeddi –Tehrani M, Protzer U, Shokri F. *Monoclonal antibodies to various epitopes of HBs antigen inhibit HBV infection*. 12th International Congress of Immunology & Allergy of Iran, April 29, 2014 – May 2, 2014, Tehran-Iran (Oral).
7. Amiri MM, Jeddi-Tehrani M, Bahadori M, Farid S, Maddah M, Khoshnoodi J, Khosravi-Eghbal R, Karimi-Jafari MH, **Rabbani H**, Shokri F. *Chimerization and humanization of an inhibitory anti-HER2 mouse monoclonal antibody*. 12th International Congress of Immunology & Allergy of Iran, April 29, 2014 – May 2, 2014, Tehran-Iran (Oral).
8. Ghalamfarsa G.H, Jadidi-Niaragh F, Khoshnoodi J, Razavi S.M, Saboor-Yaraghi A.A, Tahmasebi F, **Rabbani H**, Jeddi-Tehrani M, Shokri F. *Differential effects of vitamin A on TLR9- Induced proliferation of Normal and leukemic B-Cells from CLL patients*. 11th International Congress of Immunology & Allergy, April 26-29, 2012 (Poster).
9. Ghaemimanesh F, Babaei S, Shaban E, Zarnani A.H, Jeddi-Tehrani M, **Rabbani H**. *Anti Sortilin Antibody induces Apoptosis in ovarian cancer cell lines*. 11th International Congress of Immunology & Allergy, April 26-29, 2012 (Poster).
10. Naghi vishteh M, Seyyed Tabaei S.J, **Rabbani H**, Zarnani –A.H, Zarei O, Amini N, Haghghi A, Bayat A.A, Jeddi-Tehrani M. *Production of polyclonal antibody against SAGI (p30) Protein of Toxoplasma gorulii*. 11th International Congress of Immunology & Allergy, April 26-29, 2012 (Oral).
11. Nazila AMINI, Mohadeseh NAGHI VISHTEH, Sayeh KHANJANI, Forough TORABI, Omid ZAREI, Reza HADAVI, **Hodjattallah RABBANI**, Mahmood JEDDI-TEHRANI. *PEPTIDE-BASED MONOCLONAL ANTIBODY PRODUCTION AGAINST β -ACTIN PROTEIN*. Molecular Immunology & Immunogenetics Congress, April 27-29, 2012 (Poster).

12.Hakan Mellstedt, Mohammad Hojjat-Farsangi, Ladan Mansouri, Anders Osterborg and **Hodjattallah Rabbani**. *ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) - a Survival Factor for CLL Cells*. 53rd ASH annual meeting and exposition, san diego, America, December 10-13, 2011 (Poster).

13.Parisa Shahnazari, Saeed Zarei, **Hodjatallah Rabbani**, Amir Hassan Zarnani, Hamid Reza Khoram Khorshid, Mahmood Jeddi-Tehrani. *Prediction and Analysis of the Tertiary Structure of Human Sperm Protein Reactive with Anti-Sperm Antibody*. 9th International Congress on Obstetrics and Gynecology, November 8-11, 2011 (Oral).

14.**Hodjattallah Rabbani**, Amir Hossein Daneshmanesh, Abdul Salam Khan, Mohammad Hojjat-Farsangi, Mahmood Jeddi-Tehrani, Mohammad Mehdi Akhondi, Anders Osterborg, Fazel Shokri, Hakan Mellstedt. *Ror1 Targeting Monoclonal Antibodies Apoptosis of Chronic Lymphocytic Leukemia Cells-A Potential Novel Therapeutic Approach*. 52ND ASH ANNUAL MEETING AND EXPOSITION, December 4-7, 2010, ORLANDO, (Oral).

15.Mohammad Hojjat-Farsangi, Amir Hossein Daneshmanesh, Mahmood Jeddi-Tehrani, Anders Osterborg, Fazel Shokri, Hakan Mellstedt, **Hodjattallah Rabbani**. *T cell From CLL Patients Recognize Spontaneously Peptides Derived of The preceptor Tyrosine Kinase Ror1*. 52ND ASH ANNUAL MEETING AND EXPOSITION, December 4-7, 2010, ORLANDO, (Poster).

16.Eva Mikaelsson, Mahmood Jeddi-Tehrani, Anders Osterborg, Fazel Shokri, **Hodjattallah Rabbani**, Hakan Mellstedt. *Small Leucine Rich Proteoglycans Novel Tumor Markers In Chronic Lymphocytic Leukemia*. 52ND ASH ANNUAL MEETING AND EXPOSITION, December 4-7, 2010, ORLANDO, (Oral).

17.M. S. Poormasjedi Meibod, M. Salavati, M. Jeddi-Tehrani, A. H. Zarnani, M. Vojgani, **H. Rabbani**, M. M. Akhondi, A. R. Mahmuodi, R. Ghods. *Production of polyclonal antibodies against a Pregnancy Associated Glycoprotein's peptide: application for affinity Purification and characterization of protein from Iranian Holstein cattle placental and blood samples*. 14th International Congress of Immunology, Kobe, Japan, August 22-27, 2010 (Poster).

18.M. Salavati, M. S. Poormasjedi Meibod, M. Jeddi-Tehrani, A. H. Zarnani, M. Vojgani, **H. Rabbani**, M. M. Akhondi, A. R. Mahmuodi, R. Ghods. *The establishment of a sandwich ELISA based on a homemade polyclonal antibody for earliest detection of pregnancy associated glycoprotein*. 14th International Congress of Immunology, Kobe, Japan, August 22-27, 2010 (Poster).

19.M. Torabi Rahvar, A. Zarnani, **H. Rabbani**, E. Torkabadi, N. Mojtavavi, R. Hadavi, S. Darzi. *Establishment of a novel murine cell line expressing human Her2/neu: An appropriate model for human breast cancer*. 14th International Congress of Immunology, Kobe, Japan, August 22-27, 2010 (Poster).

20.S. Rezania, A. H. Zarnani, N. Amirmozzafari, **H. Rabbani**, M. Mosallaei, L. Katoozian, N. Rashidi. *Cell lines of divers origin have differential gene expression profile of Toll like receptor families*. 14th International Congress of Immunology, Kobe, Japan, August 22-27, 2010 (Poster).

21.Shiraz E. Savadi, M.R. Sadeghi, S. Talebi, H. Edalatkhah, **H. Rabbani**, M.A. Akhondi, Sarouiy L. AsgharPour, B. Beyk. *The relationship between the mRNA levels of spermiogenesis specific genes (PRM1, PRM2&TNP2) and normal morphology of mature sperm*. Third Asia-Pacific Forum on Andrology The Tenth Anniversary Celebration of Asian Journal of Andrology Nanjing, 10-13 October, 2009-China (Poster).

22.M. Raigani, Mohammad Reza Sadeghi, B.Yaghmaei, **H. Rabbani**, M.A. Akhondi, N. Lakpour, M. Hodjat, G. Rezaie. *Frequency of single nucleotide polymorphism of methylenetetrahydrofolate*

reductase (MTHFR) gene in oligoasthenoteratozoospermic (OAT) and normozoospermic men. Third Asia-Pacific Forum on Andrology The Tenth Anniversary Celebration of Asian Journal of Andrology Nanjing, 10-13 October, 2009-China (Poster).

23. M. Shabani, H. Asgarian Omran, J. Khoshnoodi, P. Vossough, M. Faranoush, M. Jeddi-Tehrani, **H. Rabbani**, F. Shokri. *Investigation of WT1 gene expression as a reliable tool for monitoring of minimal residual disease in acute lymphoblastic leukemia. 13th INTERNATIONAL CONGRESS OF IMMUNOLOGY, Rio De Janeiro, Brazil, August 21-25, 2007 (Poster).*

24. M. Hojjat Farsangi, M. Jeddi-Tehrani, R. A. Sharifian, S. M. Razavi, A. Shamsian, Khoramabadi, **H. Rabbani**, F. Shokri. *Immunophenotypic characterization of the leukemic B-cells in Iranian patients with chronic lymphocytic leukemia: Association between CD38 expression and disease progression. 13th INTERNATIONAL CONGRESS OF IMMUNOLOGY, Rio De Janeiro, Brazil, August 21-25, 2007 (Poster).*

25. H. Asgarian Omran, M. Shabani, T. Shahrestani, A. SarafNejad, J. Khoshnoodi, P. Vossoughe, M. Faranoush, R.A. Sharifian, M. Jeddi-Tehrani, **H. Rabbani**, F. Shokri. *Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukemia: Association to disease outcome. 13th INTERNATIONAL CONGRESS OF IMMUNOLOGY, Rio De Janeiro, Brazil, August 21-25, 2007 (Poster).*

26. A.H. Danesh manesh, E. Mikaelsson, M. Jeddi-Tehrani, A.A. Bayat, R. Ghods, M. Ostadkarampour, M. Akhondi, S. Lagercrantz, C. Larsson, A. Osterborg, F. Shokri, H. Mellstedt, **H. Rabbani**. *B Chronic lymphocytic leukemia cells express the orphan receptor tyrosine kinase ROR-1. 12th Congress of the European Hematology Association, June 07, 2007 - June 10, 2007, Vienna, Austria (Oral)*

27. Gharegozlou S, **Rabbani H**, Shokri F. *Molecular analysis of the heavy chain variable region genes of human hybridoma clones specific for coagulating factor VIII. 12th International Congress of Immunology (ICI) and 4th Annual Conference of Focis (Federation of Clinical Immunology Societies) Montréal, Quebec, Canada, 18-23 July 2004 (Poster).*

28. Fatemi F, Chamani-Tabriz L, Pakzad P, Zeraati H, **Rabbani H**. *Colonization rate of vaginal Lactobacillus species in pregnant women during labor. 15th Congress of Iranian Society for Reproductive Medicine, Iranian Journal of Reproductive Medicine, Vol. 7, Suppl 1, Winter 2009 (Poster).*

29. Fatemi F, Chamani-Tabriz L, Pakzad P, Zeraati H, **Rabbani H**. *Comparative molecular and culture-based diagnosis of vaginal colonization by group B streptococcus in pregnant women during labor. 15th Congress of Iranian Society for Reproductive Medicine, Iranian Journal of Reproductive Medicine, Vol. 7, Suppl 1, Winter 2009 (Poster).*

30. Savadi Shiraz E, Sadeghi MR, Bahmani M, Edalatkhah H, **Rabbani H**, Akhondi MA, Hodjat M. *Quantification of protamines 1, 2 and transition protein 2 transcript contents in human spermatozoa and their relation with sperm morphology. 15th Congress of Iranian Society for Reproductive Medicine, Iranian Journal of Reproductive Medicine, Vol. 7, Suppl 1, Winter 2009 (Oral).*

31. Fatemi F, Chamani Tabriz L, Pakzad P, Zeraati H, **Rabbani H**. *Prevalence of infection with group B Streptococcus (GBS) and Lactobacillus species in pregnant women at delivery room. The 17th*

Iranian Congress on Infectious Diseases and Tropical Medicine, December 20, 2008 - December 24, **2008**, (Oral).

32. Rahimi F, Chamani Tabriz L, Zeraati H, **Rabbani H**, Raigani M. *A Molecular survey on prevalence of Chlamydia trachomatis infection in pregnant woman attending OB&GY clinics of Tehran by PCR-RFLP*. The 17th Iranian Congress on Infectious Diseases and Tropical Medicine, December 20, 2008 - December 24, **2008**, (Poster).

33. Meidani M, Chamani Tabriz L, Zeraati H, Razin B, Jamali B, Gachkar L, Asgari S, **Rabbani H**, Ostad Karampour M. *Prevalence of urogenital infection with Chlamydia Trachomatis in asymptomatic men from Tehran, Iran*. 16th Iranian Congress on Infectious Diseases and Tropical Medicine, December 15, 2007- December 19, **2007**. (Poster).

34. Chamani Tabriz L, Asadi S, Zeraati H, Meidani M, Alami A, Asgari S, Sadri Ardekani H, **Rabbani H**, Jeddi-Tehrani M, Navian Ashraf M.A. *A molecular survey on genitourinary Chlamydia Trachomatis infection in men*. 16th Iranian Congress on Infectious Diseases and Tropical Medicine, December 15, 2007- December 19, **2007**. (Oral).

35. Chamani Tabriz L, Jeddi-Tehrani M, Zerrati H, Asgari S, Tarahomi M, **Rabbani H**. *A molecular survey of Chlamydia Trachomatis infection in 15-42 years old married women*. 7th International Congress on Obstetrics and Gynecology. November 09, 2007-November 13, **2007**, Tehran-Iran. (Oral).

36. Mahyar Ostadkarampour, Fazel Shokri, Mohammad Mehdi Akhondi, Pouneh Dokouhaki, Jamileh Ghasemi, Abbas Basiri, Shahram Gooran, Mahmood Jeddi-Tehrani, **Hodjattallah Rabbani**. *Expression Of Ror1 As An Orphan Receptor For Diagnosis Of Renal Cancer*. The 9th Iranian Congress of Biochemistry & the 2nd International Congress of Biochemistry and Molecular Biology Shiraz-Iran, Oct.29-Nov, 1, **2007** (Poster).

37. Eva Mikaelsson, Mahmood Jeddi- Tehrani, Anders Österborg, Fazel Shokri, **Hodjattallah Rabbani**, Håkan Mellstedt. *Fibromodulin, A Novel Tumor-Associated Antigen Exclusively Expressed In Tumor B-Cells From Patients With Chronic Lymphocytic Leukemia iwCLL* X. International Workshop on CLL. Palazzo Dei Congressi Stresa, Lake Maggiore, Italy 10-12 **October 2003**.

38. **Hodjattallah Rabbani**, Eva Mikaelsson, Amir Hossein Daneshmanesh, Alfred Luppert, Mahmood Jeddi- Tehrani, Mohammad-Reza Rezvany, Ramazan Ali Sharifian, Reza Safaie, Azam Roohi, Anders Österborg, Fazel Shokri, and Håkan Mellstedt. *Fibromodulin, A Novel Tumor-Associated Antigen Exclusively Expressed in Tumor B-Cells From all Patients with Chronic Lymphocytic Leukemia*. 8th Congress of the European Hematology Association, 12-15 June, **2003**, Lyon, France

39. Shahryar Kiaii, Mahmood Jeddi-Tehrani, Anders Österborg, Håkan Mellstedt, and **Hodjattallah Rabbani**. *Utilizing Ki67 Gene Expression for Monitoring T Cell Activation in Vaccination Studies* The Society for Biological Therapy's. 16th Annual Meeting, November 9-11, **2001** in NIH, Bethesda, USA.

40. H. Mellstedt, L. Henriksson, A. O. Abdalla, **H. Rabbani**, A. Österborg. *Combination of the Adjuvant Cytokines GM-CSF and IL-12 With the Idiotypic Vaccine Induces a Strong T Cell Immunity and Clinical Effects Might be Obtained*. 8th International Myeloma Workshop, May 4-8, **2001**, Banff, Canada

41. **Hodjattallah Rabbani**, Fariba Seyed-Mozaffari, Katja Markovic, Jan-Erik Frödin, and Håkan Mellstedt. *Immunization of Colorectal Carcinoma Patients With Avipox Vector, Expressing The Full-Length Gene of The Ga733/Epcam/Ksa Antigen*. 11th International Congress of Immunology, Stockholm, Sweden, 2001 (Poster).

42. Fariba Seyed-Mozaffari, Shahryar Kiaii, Anders Österborg, **Hodjattallah Rabbani**, and Håkan Mellstedt. *Analysis of T Cell Function in Patients With Chronic Lymphocytic Leukemia*. 11th International Congress of Immunology, Stockholm, Sweden, 2001.

43. Parviz Kokhaei, Mohammad-Reza Rezvany, Anders Österborg, **Hodjattallah Rabbani**, and Håkan Mellstedt. *Uptake of Apoptotic Tumor Cell by Autologous Dendritic Cells, A Tool for Immunotherapy in B Cell Malignancies*. 11th International Congress of Immunology, Stockholm, Sweden, 2001

44. **Hodjattallah Rabbani**, Qiang Pan, Naomi Kondo, C. I. Edvard Smith and Lennart Hammarström. *Deletion, Duplication, and Triplication in the Human IGHC Locus in Different Ethnic Groups VII Meeting of the European Society of Immunodeficiencies*, ESID June 6-9, 1996, Göteborg, Sweden (Poster and oral presentation)

45. Pan Q, **Rabbani H**, Hammarström L. *Switch Region Polymorphism in Patients With IgG3 Subclass Deficiency VII Meeting of the European Society of Immunodeficiencies*. ESID, June 6-9, 1996, Göteborg, Sweden (Poster)

46. **H. Rabbani**, C. I. E. Smith and L. Hammarström. *Analysis of the Human Ig Heavy Chain Constant Locus by PFGE in Different Ethnic Groups*. The 9th International congress of immunology", San Francisco, USA, 1995 (oral)

47. **H. Rabbani**, C. I. E. Smith and L. Hammarström. *Deletions and Duplications in the Human Immunoglobulin Heavy Chain Constant Locus*. 8th International Congress of Immunology, Budapest, Hungary, 1992 (oral).

48. L. Hammarström, **H. Rabbani**, A. Bottaro, and CIE Smith. *The Influence of Gene Duplications in the Human IGH Locus on Serum Levels of Immunoglobulins*. 11th European Immunology Meeting, June 10-12, 1991, Helsinki, Finland

Teaching Experience

- Number of Ph.D students under supervision: **3** Ph.D students: Atefe Khamooshi, Mohammad Amin Khalilzad,
- Number of Supervised Ph.D students: **11** Ph.D students: Eva Mikaelson, Amir Hossein DaneshManesh, Shila Sarial, Fatemeh Ghaemimanesh, Mona Noori Koopaei, Flora Forouzesh, Lia Farahi, Zahra Tahmasebi Fard, : Ali Ahmad Bayat, Miganos Simonian, Mozhan Haji Ghaffari
- Number of M. Sc. students under current supervision: **2** Moniba Mohebbi, ...

- Number of M. Sc. students supervised: **4** Parisa Javadi, Somaieh Roozbahani, Mahsa nikbakht, Mahsa Mohammadzadeh.
- Course No: 1784, 2004, 28 hours, Cancer Center Karolinska, Sweden
- Course no: 1490, October 20-24, 2003, 3 hours, NOVUM, Huddinge, Sweden
- Course: Neurotransmitters and their receptors-molecular biological techniques, Sweden
- Invited seminar, Department of Hematology, 2003, 2 hours, Huddinge Hospital, Sweden
- From gene to protein, Course No: 1594, October 29, 2002, 4 Hours, Cancer Center Karolinska, Sweden
- Organizing Seminar in cDNA Microarray (Affymetrix GeneChip) (Educational), March 12, 200, 1.5 Hours, Cancer Center Karolinska, Sweden
- Course: Neurotransmitters and their receptors-molecular biological techniques, Course no: 1490, 15 and 19 Oct 2001, NOVUM, Huddinge, Sweden
- Course: Biotherapy of human malignant disease (No: 1213) 2000, 4 hours, Cancer Center Karolinska, Sweden
- Seminar series, immunology, 1998, 2 hours; Stockholm University, Sweden
- Seminar series, basic immunology dental school, 1998, 6 hours; Huddinge Hospital, Sweden
- Bioinformatics Course for teachers in biology, 1996, 10 hours; Dept. of Biosciences at NOVUM, Sweden
- Bacteriology course, 1995, 20 hours theory and 20 hours practical teaching
- Hematology course, 1995, 20 hours theory and 20 hours practical teaching,

Patents by Inventor Hodjattallah Rabbani

Hodjattallah Rabbani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

DIAGNOSTIC AND THERAPEUTIC TARGET

Publication number: 20140161809

Abstract: An in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. The disclosure further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell.

Type: Application

Filed: January 30, 2014

Publication date: June 12, 2014

Applicant: Avicenna Research Institute

Inventor: Hodjattallah Rabbani

Diagnostic and therapeutic target

Patent number: 8658380

Abstract: The present invention relates to an in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. It further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell.

Type: Grant

Filed: October 28, 2011

1 of 2

5/11/18 6:50 PM

Date of Patent: February 25, 2014

Assignee: Avicenna Research Institute

Inventor: Hodjattallah Rabbani

BIOLOGICAL INHIBITORS OF ROR1 CAPABLE OF INDUCING CELL DEATH

Publication number: 20140004156

Abstract: The invention relates to antibodies and siRNA molecules for inducing cell death by the specific binding of ROR1, domains thereof of nucleotide molecules encoding ROR1. There are also provided methods involving and uses of the antibodies and siRNA molecules of the invention.

Type: Application

Filed: December 10, 2010

Publication date: January 2, 2014

Inventors: Hakan Mellstedt, Hodjattallah Rabbani, Ingrid Teige

DIAGNOSTIC AND THERAPEUTIC TARGET

Publication number: 20130039917

Abstract: The present invention relates to an in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. It further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell.

Type: Application

Filed: October 28, 2011

Publication date: February 14, 2013

Inventor: Hodjattallah Rabbani

2 of 2

5/11/18 6:50 PM



بسمه تعالی

جناب آقای الیاسی

رئیس محترم اداره ثبت اختراعات

با سلام

احتراماً، پیرو نامه استعلام به شماره ۱۳۹۶۵۰۷۴۰۰۰۳۰۱۰۶۸۳ مورخ ۱۳۹۶/۱۱/۲۸ آن اداره در خصوص ثبت اختراع با عنوان " تولید آنتی بادی مونوکلونال اختصاصی بر ضد Sortilin بیان شونده در سلول های خونی بیماران مبتلا به لوسمی لنفوئیدی مزمن به عنوان محصولی با عملکرد تشخیصی و درمانی " به شماره اظهارنامه ۱۳۹۶۵۰۱۴۰۰۰۳۰۱۲۵۳۳ باستحضار می‌رساند موضوع درخواست در کمیته مالکیت فکری انستیتو مطرح و طبق بند ۵ مصوبات جلسه شماره ۹۷/۵/۰۷/۹۷/۰۵/۰۷، موضوع اختراع در صورت تغییر ادعاینامه و شرح و توصیف (به پیوست) سه شرط نوآوری، گام‌ابتکاری و کاربرد صنعتی را احراز نموده و پیگیری روند ثبت آن بلامانع است.

ضمناً یادآور می‌شود درخواست ثبت اختراع جاری از شمول تبصره د ماده ۴ قانون ثبت اختراعات خارج است و متقاضیان در روند بررسی و داوری هیچگونه مداخله و مشارکت ندارد. همچنین اعلام می‌دارد کلیه بررسی و داوری‌ها در کمیته مالکیت فکری انستیتو پاستور که یک کمیته مستقل است انجام می‌شود لکن انستیتو پاستور ایران هیچگونه مسئولیتی در قبال تولید، فروش یا صادرات محصولات مشتق از این اختراع ندارد.

رد	تائید	وضعیت	رد	تائید	وضعیت
	✓	۵- اختراع واحد		✓	۱- نوآوری
	✓	۶- کفایت افشاء		✓	۲- گام ابتکاری
	✓	۷- امکان بررسی مجدد پرونده توسط مرجع دیگر حسب صلاحدید		✓	۳- کاربرد صنعتی
	✓	۸- نظر نهایی کمیته مالکیت فکری انستیتو پاستور		✓	۴- شفافیت ادعاها

دکتر سعید بوذری
معاون تحقیقات، فناوری و آموزش



تلفن: ۶۶۹۵۳۳۱۱-۲۰ فاکس: ۶۶۴۶۵۱۳۲

صفحه الکترونیکی: <http://www.pasteur.ac.ir>

نشانی: تهران - خیابان پاستور - پلاک ۶۹ کد پستی: ۱۳۱۶۴

پست الکترونیکی: office@institute.pasteur.ac.ir



سازمان ثبت اسناد و املاک کشور

گواهی نامه ثبت اختراع



۰۲۸۲۵۰ الف/۸۹

شخصات مالک: حجت اله ربانی، شماره ملی: ۰۰۵۰۳۲۹۶۸۵، نشانی: تهران-شهرک نفت-خیابان ۲۹ اسفند-خیابان بیست و دوم، پلاک ۱۴، برج کوهپایه، طبقه نهم، واحد ۹۵-شرکت پادزا پادتن پژوه، کد پستی: ۱۴۶۹۸۶۳۹۷۱، تابعیت جمهوری اسلامی ایران

شخصات مخترع: حجت اله ربانی، شماره ملی: ۰۰۵۰۳۲۹۶۸۵، نشانی: تهران-شهرک نفت-خیابان ۲۹ اسفند-خیابان بیست و دوم-پلاک ۱۴، برج کوهپایه، طبقه ۹-واحد ۹۵، شرکت پادزا پادتن پژوه، کد پستی: ۱۴۶۹۸۶۳۹۷۱، تابعیت جمهوری اسلامی ایران

عنوان اختراع: اپتی بادی بر مبنای پیپتید ضد فیبرومودولین (FMOD) با خصوصیت تشخیص فیبرومودولین سطح سلولی به عنوان یک هدف تشخیصی و درمانی در بیماران مبتلا به سرطان

طبقه بندی بین المللی A61K 39/395; A61P 35/00; C07K 16/28

حق تقدم:

شماره و تاریخ اظهارنامه اصلی: کل ثبت:

شماره و تاریخ ثبت اختراع:	شماره و تاریخ ثبت اظهارنامه:	ذات حمایت: ۲۰ سال از تاریخ
۱۳۹۷/۰۶/۱۴ - ۹۶۶۹۱	۱۳۹۶/۰۷/۲۶ - ۱۳۹۶۵۰۱۴۰۰۰۳۰۰۸۶۱۳	۱۳۹۶/۰۷/۲۶ - ۱۳۹۶/۰۷/۲۶
امضاء:	تاریخ: ۶/۳۰/۹۷	مهر داد الیاسی

مدت حمایت اختراع 20 سال از تاریخ تسلیم اظهارنامه می باشد مگر آنکه اسقاط سالیانه اختراع در مواعید مقرر توسط مقامات پرداخت شود
* تمام گواهی نامه، توصیف ادعا، نظام توصیف و نقشه
* در صورت ندرت مخترع، مالکین و یا شیرت در رتبه بزرگ گواهی نامه می باشد

۳۵۰
سال



سازمان ثبت اسناد و املاک کشور

کوپایی نامه ثبت اختراع



۰۲۸۳۴۹ الف / ۸۹

حجت اله ربانی، شماره ملی: ۰۰۵۰۳۲۹۶۸۵، نشانی: تهران-شهرک نفت-خیابان ۲۹ اسفند-خیابان بیست و دوم-پلاک ۱۳-برج کوهپایه-طبقه نهم-واحد ۹۵-شرکت پادزا پادتن پژوه، کد پستی: ۱۴۶۹۸۶۳۹۷۱، تابعیت جمهوری اسلامی ایران

حجت اله ربانی، شماره ملی: ۰۰۵۰۳۲۹۶۸۵، نشانی: تهران-شهرک نفت-خیابان ۲۹ اسفند-خیابان بیست و دوم-پلاک ۱۳-برج کوهپایه-طبقه نهم-پلاک ۹۵-شرکت پادزا پادتن پژوه، کد پستی: ۱۴۶۹۸۶۳۹۷۱، تابعیت جمهوری اسلامی ایران

عنوان اختراع: تولید آنتی بادی منوکلونال اختصاصی ضد مارکر سرطانی Rof1 و متصل به ماده رادیویزوتوپ ^{۶۷}Ga به عنوان محصولی اختصاصی جهت تسویبربرداری و تشخیص میتلابان بد سرطان پستان

طبقه بندی بین المللی A61P 35/00; A61K 39/395; C07K 16/28

حق تقدم:

شماره و تاریخ اظهار نامه اصلی:
 عمل ثبت:

شماره و تاریخ ثبت اختراع:	شماره و تاریخ ثبت اظهار نامه:	مدت حمایت: ۲۰ سال از تاریخ
۱۴۹۷/۰۶/۱۸ - ۱۶۶۸۳	۱۳۹۶/۰۹/۰۹ - ۱۳۹۶۵۰۱۴۰۰۰۲۰۱۰۳۴۴	۱۴۹۶/۰۹/۰۹ تا ۱۳۹۶/۰۹/۰۹
مخترع:	تایید:	مهر داد الیاسی

مدت حمایت اختراع 20 سال از تاریخ تسلیم اظهارنامه می باشد موطوبه اینکه اقسام سالانه اختراع در مواعد مقرر توسط متقاضی پرداخت شود

* تمام کوپایی نامه: توصیف ادعا، شماره توصیف و متن

* در صورت تعدد مخترعین، مالکین یا تغییرات در انب، شرح تدریج در نظر کوپایی نامه می باشد.

۱۳۹۷/۰۶/۱۸

۵۵۰
سال



قوه قضائیه

سازمان ثبت اسناد و املاک کشور

گواهی نامه ثبت اختراع



۰۲۸۳۵۱ الف / ۸۹

شخصات مالک: حجت اله ربانی، شماره ملی: ۰۰۵۰۳۲۹۶۸۵، نشانی: تهران-شهرک نفت-خیابان ۲۹ اسفند، خیابان بیست و دوم، پلاک ۱۲، برج کوهپایه، طبقه نهم، واحد ۹۵، شرکت پادزا پادتن پژوه، کد پستی: ۱۴۶۹۸۶۳۹۷۱، تابعیت جمهوری اسلامی ایران

شخصات مخترع: حجت اله ربانی، شماره ملی: ۰۰۵۰۳۲۹۶۸۵، نشانی: تهران-شهرک نفت-خیابان ۲۹ اسفند-خیابان بیست و دوم-پلاک ۱۲، برج کوهپایه-طبقه نهم-واحد ۹۵-شرکت پادزا پادتن پژوه، کد پستی: ۱۴۶۹۸۶۳۹۷۱، تابعیت جمهوری اسلامی ایران

عنوان اختراع: تولید آنتی بادی منوکلونال اختصاصی بر ضد **Sortilin** بیان شونده در سلول های خونی بیماران مبتلا به لوسمی لنفوبیدی مزمن، به عنوان محصولی با عملکرد تشخیصی و درمانی

طبقه بندی بین المللی: A61P 35/02; A61K 39/395; C07K 16/28

تق تقدم:

شماره و تاریخ اظهار نامه اصلی:

کل ثبت:

مدرت حمایت: ۲۰ سال از تاریخ	شماره و تاریخ ثبت انحصاری:	شماره و تاریخ ثبت اختراع:
۱۳۹۶/۱۰/۳۰	۱۳۹۶/۱۰/۳۰	۱۳۹۷/۰۶/۱۹
۱۴۱۶/۱۰/۳۰	۱۳۹۶/۱۰/۳۰	۱۳۹۷/۰۶/۱۹

اداره مالکیت صنعتی * * * * * مرکز مالکیت صنعتی
رئیس اداره ثبت اختراعات
مهرداد الیاسی
تاریخ: ۱۳۹۷/۰۶/۱۹
امضاء:

مدت حمایت اختراع 20 سال از تاریخ تسلیم اظهارنامه می باشد مگر آنکه طبق اساطح سالانه اختراع در مواعید مقرر توسط متقاضی پرداخت شود
* نام گواهی نامه، توصیف ادعا، ظاهر توصیف و شرح
* در صورت تعدد مخترعین، مالکین و یا ثبت اختراع مراتب شرح ندرج در فهرست نامی باشد

۱۳۹۷/۰۶/۱۹

شناسه یکتا: ۱۴۰۲۵۰۳۴۰۰۰۳۰۰۰۷۴۳
رمز تصدیق: ۳۷۱۷۲۷



سازمان ثبت اسناد و املاک کشور
کواهی نامه ثبت اختراع

شماره اظهارنامه اختراع: ۱۴۰۱۵۰۱۴۰۰۰۳۰۰۰۶۴۲۴
شماره ثبت اختراع: ۱۰۹۲۷۰
تاریخ ثبت اظهارنامه اختراع: ۱۴۰۱/۰۹/۱۰
تاریخ ثبت اختراع: ۱۴۰۲/۰۳/۰۱

عنوان اختراع:

آنتی بادی مونوکلونال در برابر نشانگر سلول های بنیادی Nanog به عنوان ابزار تشخیصی و درمانی سرطان
مشخصات مالک:

حجت اله ربانی، شماره ملی: ۰۰۵۰۳۳۹۶۸۵، نشانی: استان تهران، شهرستان تهران، بخش مرکزی، شهر تهران، بیمه، خیابان شهید توج فلسفی [بیمه ۴]،
بن بست تک، پلاک ۵ طبقه همکف، کد پستی: ۱۲۹۲۸۱۳۹۳۵، تابعیت جمهوری اسلامی ایران

مشخصات مخترع:

حجت اله ربانی، شماره ملی: ۰۰۵۰۳۳۹۶۸۵، نشانی: استان تهران، شهرستان تهران، بخش مرکزی، شهر تهران، بیمه، خیابان شهید توج فلسفی [بیمه ۴]،
بن بست تک، پلاک ۵ طبقه همکف، کد پستی: ۱۲۹۲۸۱۳۹۳۵، تابعیت جمهوری اسلامی ایران
نیلوفر صادقی، شماره ملی: ۰۰۱۲۰۹۲۹۳۲، نشانی: استان تهران، شهرستان تهران، بخش مرکزی، شهر تهران، محله بیمه، خیابان شهید توج فلسفی
[بیمه ۴]، بن بست تک، پلاک ۵، طبقه همکف، کد پستی: ۱۲۹۲۸۱۳۹۳۵، تابعیت جمهوری اسلامی ایران

طبقه بندی بین المللی:

A61K 39/395; A61P 35/00; G01N 33/00

مدت حمایت از تاریخ: ۱۴۰۱/۰۹/۱۰ تا تاریخ: ۱۴۲۷/۰۹/۱۰ منوط به پرداخت اقساط سالیانه وفق ماده ۱۶ قانون و ۶۶ آیین نامه اجرایی در مواعید مقرر می باشد.

رئیس اداره ثبت اختراعات اعمامون: فرحناز شیروانی

تاریخ: ۱۴۰۲/۰۳/۳۰ امضا:

رئیس اداره ثبت اختراعات
از طرف شیروانی

مستندات گواهی نامه شامل توصیف، ادعاینامه خلاصه و نقشه در زمان تصدیق اصالت در لیتک
نمشی وسایر مشخصات مخترعان، مالکان ویا نئیرات، مراتب به شرح مندرج در پیوست گواهی نامه می باشد

شماره یکتا: ۱۴۰۲۵۰۳۴۰۰۰۳۰۰۰۷۴۵
رمز تصدیق: ۵۷۱۸۱۶



قوه قضائیه

سازمان ثبت اسناد و املاک کشور

گواهی نامه ثبت اختراع

شماره اظهارنامه اختراع: ۱۴۰۱۵۰۱۴۰۰۰۳۰۰۶۳۳
تاریخ ثبت اظهارنامه اختراع: ۱۴۰۱/۰۹/۰۳

شماره ثبت اختراع: ۱۰۸۹۶۰
تاریخ ثبت اختراع: ۱۴۰۲/۰۱/۰۶

عنوان اختراع:

ایجاد فرآورده آنتی بادی ضد واریانت B۱ مارکر سلول بنیادی OCT۴ جهت تشخیص و درمان سرطان
مشخصات مالک:

حجت اله ربانی، شماره ملی: ۰۰۵۰۳۳۹۶۸۵، نشانی: استان تهران، شهرستان تهران، بخش مرکزی، شهر تهران، بیمه، خیابان شهید توج فلسفی [بیمه ۴]،
بن بست تک، پلاک ۵ طبقه همکف، کد پستی: ۱۳۹۲۸۱۳۹۳۵، تابعیت جمهوری اسلامی ایران

مشخصات مخترع:

حجت اله ربانی، شماره ملی: ۰۰۵۰۳۳۹۶۸۵، نشانی: استان تهران، شهرستان تهران، بخش مرکزی، شهر تهران، بیمه، خیابان شهید توج فلسفی [بیمه ۴]،
بن بست تک، پلاک ۵ طبقه همکف، کد پستی: ۱۳۹۲۸۱۳۹۳۵، تابعیت جمهوری اسلامی ایران

طبقه بندی بین المللی:

A۶۱P ۲۱/۰۲; A۶۱P ۳۵/۰۰; G۰۱N ۳۳/۰۰



مدت حمایت از تاریخ: ۱۴۰۱/۰۹/۰۳ تا تاریخ: ۱۴۲۷/۰۹/۰۳ منوط به پرداخت قسطا سالانه وفق ماده ۱۶ قانون و ۶۶ آیین نامه اجرایی در موعد مقرر می باشد

امضا: 
رئیس اداره ثبت اختراعات
از طرف شیروانی

تاریخ: ۱۴۰۲/۰۳/۳۱ امضا: فرحناز شیروانی

مستندات گواهی نامه شامل توصیف، ادعاینامه خلاصه و نقشه در زمان تصدیق اصالت در لیتک
نشانی و سایر مشخصات مخترعان، مالکان و یا نمایندگان، مراتب به شرح مندرج در پیوست گواهی نامه می باشد

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 June 2024 (06.06.2024)



(10) International Publication Number
WO 2024/115998 A1


- (51) International Patent Classification:
G01N 33/53 (2006.01) *G01N 33/577* (2006.01)
G01N 33/574 (2006.01)
- (21) International Application Number:
PCT/IB2023/061410
- (22) International Filing Date:
11 November 2023 (11.11.2023)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
140150140003006424
01 December 2022 (01.12.2022) IR
- (71) Applicant: **PADZA-PADTAN-PAJHOOH** [IR/IR]; No. 5, Tak alley, Kooy-e-Bimeh, Tehran Province, Tehran, 1393873935 (IR).
- (72) Inventors: **RABBANI, Hodjattallah**; No. 5, Tak alley, Kooy-e-Bimeh, Tehran Province, Tehran, 1393873935 (IR). **SADEGHI, Niloufar**; No. 5, Tak alley, Kooy-e-Bimeh, Tehran Province, Tehran, 1393873935 (IR). **MOHAM-**

MADI, Javad; No. 5, Tak alley, Kooy-e-Bimeh, Tehran Province, Tehran, 1393873935 (IR).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: AN IN VITRO METHOD FOR ASSESSING THE RISK THAT A SUBJECT SUFFERS FROM CANCER

Figure 5



(57) Abstract: The present invention is related to an in vitro method for assessing the risk that a subject suffers from a cancer. The invention also provides a method for detecting of cells in a test tissue sample from the subject that express Nanog on the cell membrane including breast, liver, lung, bladder, and cervical cancer and any cancer cell expressing the membrane isoform of Nanog.

[Continued on next page]

WO 2024/115998 A1